Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
- Gross Profit Margin
- The gross profit margin has remained relatively stable over the analyzed periods, fluctuating narrowly between approximately 84.6% and 87.2%. Despite minor fluctuations quarter to quarter, the margin reflects a consistently high level of profitability on core activities, with no evident long-term upward or downward trend.
- Operating Profit Margin
- The operating profit margin exhibits a clear downward trend over time. Starting at 43.37% in the first quarter, it increased to a peak of 55.67% by the end of 2021 but then steadily declined throughout subsequent periods, reaching around 25.89% by the third quarter of 2025. This decline suggests rising operating costs or reduced operating efficiency impacting earnings before interest and taxes.
- Net Profit Margin
- The net profit margin followed a similar pattern to the operating profit margin, peaking near 51.65% in late 2021 before gradually diminishing to levels slightly above 30% in the most recent quarters. Although it recovers somewhat starting in early 2024, the margin remains well below its earlier highs. This downward progression indicates that after accounting for all expenses and taxes, overall profitability has contracted compared to the earlier periods.
- Return on Equity (ROE)
- Return on equity shows a significant decline from the initial quarters, decreasing from above 40% in 2021 to levels near 15% by 2025. This consistent reduction points to a diminishing capability to generate net income from shareholders’ equity, which could result from lower net profits or changes in equity structure.
- Return on Assets (ROA)
- Return on assets trends downward from a peak of approximately 31.75% to just over 11% in the later quarters. This decline suggests a diminished efficiency in using company assets to produce profits, potentially reflecting increased asset bases without corresponding net income increases or reduced profitability.
Return on Sales
Return on Investment
Gross Profit Margin
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Gross profit margin = 100
× (Gross profitQ3 2025
+ Gross profitQ2 2025
+ Gross profitQ1 2025
+ Gross profitQ4 2024)
÷ (RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Revenues exhibit a fluctuating pattern over the observed periods. Initial quarters in 2021 show notable volatility, with revenue rising from $2,528,700 thousand to $5,138,500 thousand, then declining to $3,452,800 thousand, followed by a rebound to $4,951,700 thousand. In 2022, revenues demonstrate relative stability with moderate incremental growth from $2,965,100 thousand to $3,414,400 thousand by year-end. The trend continues with slight fluctuations through 2023 to early 2025, displaying gradual increases interspersed with periodic decreases, finishing near $3,754,300 thousand.
- Gross Profit Trends
- Gross profit mirrors the revenue pattern, showing significant variations initially in 2021, including a peak of $4,444,800 thousand and notable dips, before stabilizing around mid-2022. From 2022 onward, gross profit exhibits mild upward trends overall, with some quarters demonstrating slight decreases, particularly in the early months of 2025. The data highlights intermittent growth phases with some temporary contractions, culminating in a gross profit near $3,232,700 thousand by the last quarter evaluated.
- Gross Profit Margin Analysis
- The gross profit margin remains consistently high throughout the periods, predominantly ranging between 84.65% and 87.18%. This indicates strong profitability relative to revenues, with only modest fluctuation seen over time. Margins peaked at 87.18% in late 2021 and generally maintained above 85% from 2022 through 2025, suggesting effective cost management in relation to revenue generation despite the variations in absolute financial results.
- Overall Observations
- The company demonstrates resilience in its financial performance, with revenues and gross profits experiencing volatility but generally trending upward over the medium term. The stability of the gross profit margin above 84% implies efficient operational controls and pricing strategies. The observed fluctuations in revenue and gross profit could be impacted by external market conditions or internal strategic changes; however, the maintenance of strong margins underscores an ability to retain profitability across different market cycles.
Operating Profit Margin
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Income from operations | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Operating profit margin = 100
× (Income from operationsQ3 2025
+ Income from operationsQ2 2025
+ Income from operationsQ1 2025
+ Income from operationsQ4 2024)
÷ (RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data over multiple quarters reveals distinct patterns and trends in income from operations, revenues, and operating profit margin for the company.
- Income from Operations
- The income from operations shows considerable volatility across the observed periods. Initial quarters experienced a surge, peaking around mid-2021, followed by sharp declines. Subsequent quarters exhibit fluctuations with no clear sustained upward or downward trend. The values generally fluctuate between approximately 590,000 to 3,300,000 USD in thousands, indicating varying operational performance across quarters with some recovery periods, though the recent quarters towards 2025 show a relatively lower and more stable range.
- Revenues
- Revenues display a similarly volatile pattern but with less pronounced swings compared to income from operations. The earlier quarters around 2021 show higher revenue values exceeding 5,000,000 USD in thousands, followed by a drop in mid-2022. From 2023 onwards, revenues mostly stabilize within a narrower range between approximately 3,000,000 and 3,800,000 USD in thousands. This suggests a period of more consistent sales or service generation but without the peaks seen in earlier quarters.
- Operating Profit Margin
- The operating profit margin shows a clear downward trend throughout the time frame. Starting above 43% in early 2021 and reaching peaks upward of 55% within that year, it steadily declines quarter by quarter. By the later periods approaching 2025, the margin reduces to just below 26%. This declining margin suggests increasing operational costs or diminishing efficiency in converting revenues to profits over time, despite relatively stable revenues in later quarters.
Overall, the analysis indicates that while the company maintains considerable revenue generation, the efficiency as measured by operating profit margin is decreasing consistently. Income from operations is characterized by high volatility, possibly reflecting fluctuating cost structures or operational challenges. The stability in revenues paired with declining profitability margins may warrant strategic examination of cost management and operational efficiency going forward.
Net Profit Margin
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Net profit margin = 100
× (Net incomeQ3 2025
+ Net incomeQ2 2025
+ Net incomeQ1 2025
+ Net incomeQ4 2024)
÷ (RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Income Trends
- The net income experienced significant fluctuations over the analyzed periods. Initially, it showed strong performance, peaking notably in June 2021 at approximately 3.1 billion USD, followed by a decline through the end of 2021. In 2022, net income decreased compared to the 2021 peak, with the lowest point around June 2022 at approximately 852 million USD. Starting from 2023, net income displayed a moderate recovery, reaching around 1.46 billion USD by September 2025, with some periodic volatility observed across quarters.
- Revenue Patterns
- Revenues demonstrated a variable pattern with occasional strong growth quarters. The highest revenue was recorded in June 2021 at over 5.1 billion USD, after which revenues declined and stabilized around 3 to 3.7 billion USD in subsequent quarters. From 2023 through the projected quarters in 2025, revenues showed a generally positive trend, gradually increasing and occasionally surpassing 3.7 billion USD, indicating recovery and growth beyond the post-2021 decline.
- Net Profit Margin Analysis
- The net profit margin declined steadily from early 2021 to the end of 2022. It started at a robust 43.53% in March 2021, peaked near 51.65% in September 2021, then decreased significantly to about 30.14% by December 2022. From 2023 onward, the margin stabilized in the low 30% range, fluctuating between approximately 29.45% and 33.61%, suggesting a return to more consistent profitability despite lower margins compared to the early period.
- Overall Financial Insights
- The data suggest a period of high profitability and revenue in early to mid-2021, followed by a notable contraction throughout late 2021 and much of 2022. While net income and profit margins decreased substantially after their peaks, revenue showed some resilience with moderate recovery trends in the later quarters. The stabilization of net profit margins around 30% and steady revenue increases in 2023 through 2025 denote a gradual financial strengthening, though profit margins have not returned to their highest earlier levels. The combination of recovering revenues and improved income levels indicates an effective adaptation to previous challenges or market conditions.
Return on Equity (ROE)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
ROE = 100
× (Net incomeQ3 2025
+ Net incomeQ2 2025
+ Net incomeQ1 2025
+ Net incomeQ4 2024)
÷ Stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several key trends in net income, stockholders' equity, and return on equity (ROE) over the analyzed periods.
- Net Income
- The net income exhibits notable volatility throughout the quarters. Initially, it peaked sharply at nearly 3.1 billion USD in mid-2021, followed by a decline to just under 1 billion USD by the first quarter of 2022. The subsequent quarters up to late 2023 show a moderate recovery with net income fluctuating roughly between 800 million and 1.16 billion USD. In 2024, net income again rose significantly, surpassing 1.4 billion USD in mid-2024 before falling back closer to the 900 million USD range by early 2025. Towards the end of the observed timeline, net income increased once more, reaching about 1.46 billion USD by the third quarter of 2025. This pattern suggests the company experiences cyclical earnings performance with intermittent peaks and troughs rather than steady growth.
- Stockholders' Equity
- The stockholders' equity consistently increased over the entire period. Starting at approximately 12 billion USD in early 2021, equity rose steadily each quarter, reaching nearly 31 billion USD by late 2025. The growth appears mostly linear, indicating ongoing capitalization, retained earnings accumulation, or possible equity injections. The consistent upward trend in equity contrasts with the more variable net income, suggesting a strong capital base that is gradually expanding.
- Return on Equity (ROE)
- ROE started at a high level above 33% in early 2021, reaching its peak near 43% at the end of that year. Following this peak, ROE displayed a declining trend through 2022 and 2023, dropping to around 15% by the end of 2023. Throughout 2024 and into 2025, ROE stabilized in the mid-teens, fluctuating narrowly between approximately 14.3% and 15.9%. This decline and subsequent stabilization at a lower ROE level reflect diminishing net income efficiency relative to equity, likely influenced by the rapid growth in equity surpassing net income growth. The company hence demonstrates strong but gradually decreasing profitability on equity investment over time.
In summary, while the company has been successful in growing its equity base steadily, net income has been more volatile with multiple fluctuations. Meanwhile, ROE has declined from very high initial levels and stabilized at a moderate range, indicating a shift towards more balanced but less aggressive profit generation relative to equity.
Return on Assets (ROA)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
ROA = 100
× (Net incomeQ3 2025
+ Net incomeQ2 2025
+ Net incomeQ1 2025
+ Net incomeQ4 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income
- The net income demonstrates significant volatility across the observed periods. Initially, there is a notable peak in the second quarter of 2021, followed by a sharp decline in the first quarter of 2022. Subsequently, net income experiences fluctuations with moderate increases and decreases throughout 2023 and 2024, showing sporadic recovery in certain quarters but overall lacking a consistent upward or downward trend. The later quarters of 2024 and 2025 exhibit moderate positive results, but these are substantially lower than the earlier peaks observed in 2021.
- Total Assets
- Total assets present a steady and continuous growth throughout the entire period. The asset base expands consistently quarter over quarter without any signs of decline or plateau. This persistent increase reflects ongoing asset accumulation or investment, indicating growth in the company’s resource base, reaching its highest points in the most recent quarters of 2025.
- Return on Assets (ROA)
- ROA exhibits a pronounced downward trend over time. Initially, ROA reaches relatively high values exceeding 28%, peaking around late 2021. However, following this peak, ROA progressively declines, dropping to levels near 11% to 12% in the more recent quarters. This trend suggests diminishing profitability relative to the asset base, implying the company is generating less income per unit of asset than in earlier periods despite the expansion of total assets.
Overall, the analysis shows that although the asset base is expanding steadily, profitability metrics are contracting, indicating potential challenges in asset utilization or earnings efficiency. The inconsistent net income further underscores variability in financial performance, reinforcing the observation of decreasing returns on the growing asset pool.